Post-induction undetectable flow minimal residual disease ameliorates the high risk determined by FISH among newly diagnosed multiple myeloma

被引：0
|
作者：
Seval, Guldane Cengiz [1 ]
Dalva, Klara [1 ]
Bakanay, Sule Mine [1 ]
Soydan, Ender [1 ]
Ilhan, Osman [1 ]
Beksac, Meral [1 ]
Sonmez, Gulcin Miyase [1 ]
机构：
[1] Ankara Univ, Dept Hematol, Sch Med, Ankara, Turkiye
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-132
引用
收藏
页码：S108 / S108
页数：1
相关论文
共 50 条
  • [1] Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma
    Yang, Peiyu
    Xu, Weiling
    Liang, Xinyue
    Yu, Shanshan
    Yi, Xingcheng
    Liu, Mengmeng
    Tian, Mengru
    Yue, Tingting
    Zhang, Yingjie
    Yan, Yurong
    Hu, Zhongli
    Guo, Qiang
    Zhang, Nan
    Wang, Jingxuan
    Sun, Xiaoxiao
    Hu, Rui
    Kumar, Shaji K.
    Dai, Yun
    Jin, Fengyan
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (03) : E61 - E64
  • [2] Post-Induction Undetectable Minimal Residual Disease at 10 -5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk
    Seval, Guldane Cengiz
    Dalva, Klara
    Oz, Dilek
    Bakanay, Sule Mine
    Soydan, Ender
    Gurman, Gunhan
    Ilhan, Osman
    Beksac, Meral
    BLOOD, 2021, 138
  • [3] Genetically undetectable and negative minimal residual disease after induction therapy are equally important for survival in multiple myeloma
    Cui, Jian
    Liu, Jiahui
    Fan, Huishou
    Yan, Wenqiang
    Xu, Jingyu
    Du, Chenxing
    Deng, Shuhui
    Qiu, Lugui
    An, Gang
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S59 - S60
  • [4] Genetically Undetectable and Negative Minimal Residual Disease after Induction Therapy Are Equally Crucial for Survival in Multiple Myeloma
    Cui, Jian
    Liu, Jiahui
    Fan, Huishou
    Qiu, Lugui
    Anderson, Kenneth C.
    An, Gang
    BLOOD, 2022, 140 : 7185 - 7186
  • [5] Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma
    Schinke, Carolina
    Deshpande, Shayu
    Mitchell, Alan
    Faham, Malek
    Patel, Purvi
    Thanendrarajan, Sharmilan
    Mohan, Meera
    Mathur, Pankaj
    Matin, Aasiya
    Radhakrishnar, Muthukumar
    Tytarenko, Ruslana
    Stephens, Owen W.
    van Rhee, Frits
    Zangari, Maurizio
    Jethava, Yogesh
    Petty, Nathan
    Alapat, Daisy V.
    Johnson, Sarah K.
    Epstein, Joshua
    Barlogie, Bart
    Davies, Faith E.
    Heuck, Christoph
    Hoering, Antje
    Weinhold, Niels
    Morgan, Gareth J.
    BLOOD, 2015, 126 (23)
  • [6] Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
    San-Miguel, Jesus
    Avet-Loiseau, Herve
    Paiva, Bruno
    Kumar, Shaji
    Dimopoulos, Meletios A.
    Facon, Thierry
    Mateos, Maria-Victoria
    Touzeau, Cyrille
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Cook, Gordon
    Cavo, Michele
    Quach, Hang
    Ukropec, Jon
    Ramaswami, Priya
    Pei, Huiling
    Qi, Mia
    Sun, Steven
    Wang, Jianping
    Krevvata, Maria
    DeAngelis, Nikki
    Heuck, Christoph
    Van Rampelbergh, Rian
    Kudva, Anupa
    Kobos, Rachel
    Qi, Ming
    Bahlis, Nizar J.
    BLOOD, 2022, 139 (04) : 492 - 501
  • [7] Outcomes of Post-Induction Bortezomib Therapy in Patients with Newly diagnosed Multiple Myeloma: A Multi-Center Retrospective Observational Study
    Luttwak, Efrat
    Gatt, Moshe
    Lavi, Noa
    Tadmor, Tamar
    Kreiniz, Natalia
    Benyamini, Noam
    Horowitz, Netanel
    Suriu, Celia
    Avivi, Irit
    Trestman, Svetlana
    Mittelman, Moshe
    Ram, Ron
    Rouvio, Ory
    Cohen, Yael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E296 - E296
  • [8] Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients
    Oliva, Stefania
    Genuardi, Elisa
    Belotti, Angelo
    Frascione, Pio Manlio Mirko
    Galli, Monica
    Capra, Andrea
    Offidani, Massimo
    Vozella, Federico
    Zambello, Renato
    Auclair, Daniel
    Siniscalchi, Agostina
    Yesil, Jennifer
    Annibali, Ombretta
    Kirsch, Ilan M.
    Caltagirone, Simona
    Jacob, Allison P.
    Ballanti, Stelvio
    Palmas, Angelo D.
    Ledda, Antonio
    Corradini, Paolo
    Omede, Paola
    Cavo, Michele
    Musto, Pellegrino
    Boccadoro, Mario
    Gay, Francesca
    BLOOD, 2019, 134
  • [9] Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease
    Desai, Ami, V
    Applebaum, Mark A.
    Karrison, Theodore G.
    Oppong, Akosua
    Yuan, Cindy
    Berg, Katherine R.
    MacQuarrie, Kyle
    Sokol, Elizabeth
    Hall, Anurekha G.
    Pinto, Navin
    Wolfe, Ian
    Mody, Rajen
    Shusterman, Suzanne
    Smith, Valeria
    Foster, Jennifer H.
    Nassin, Michele
    LaBelle, James L.
    Bagatell, Rochelle
    Cohn, Susan L.
    CANCER, 2022, 128 (15) : 2967 - 2977
  • [10] Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted Therapy
    Mo, Clifton C.
    Hartley-Brown, Monique A.
    Midha, Shonali
    Richardson, Paul G.
    CANCERS, 2023, 15 (24)
12345